Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediately if any of the following side effects occur while taking hydroxychloroquine: Incidence not known Some side effects of hydroxychloroquine may occur that usually do not need medical attention. Is coughing normal when taking plaquenil Plaquenil generic images Autofluorescence imaging in plaquenil Chloroquin bestellen anti malaria Pigmentation appeared after a median duration of hydroxychloroquine treatment of 32 months with a median cumulative dose of 361 g. Overall, two patients reported that the appearance of pigmented lesions was preceded by the occurrence of ecchymotic areas following microtrauma. Hydroxychloroquine-associated hyperpigmentation in an elderly woman was clinically misinterpreted as elder abuse resulting in notification of Adult Protective Services by the clinician; skin biopsy subsequently confirmed the etiology of her diffuse black and blue dyschromia. Hydroxychloroquine is a well-tolerated medication for various rheumatologic and dermatologic conditions. Its main side effects are gastrointestinal upset, skin rash, headache, and ocular toxicity1. Within the eye, hydroxychloroquine can adversely impact the cornea, ciliary body, and retina1 Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. These side effects may go away during treatment as your body adjusts to the medicine. Hydroxychloroquine hyperpigmentation treatment Hydroxychloroquine Uses, Dosage & Side Effects -, Hydroxychloroquine-Associated Chloroquine davis Hydroxychloroquine Plaquenil is not a new therapy. It has been used in rheumatology for decades and it's proven a very useful medication. Plaquenil Pigmentation - BJC Health. Hydroxychloroquine toxicity - EyeWiki. Annular Atrophic Lichen Planus Responds to Hydroxychloroquine and.. The only treatment for this skin hyperpigmentation is discontinuing hydroxychloroquine, but it can take several months to improve the skin changes. Complete clearance is rare.2 Treatment with HCQ was discontinued definitively because of skin pigmentation in 2 patients who reported a gradual incomplete fading of hyperpigmentation. Among patients who continued HCQ treatment n = 22, an improvement in pigmented lesions was reported in 6, despite the maintenance of a similar daily dose of HCQ. In the treatment of porphyria cutanea tarda, hydroxychloroquine 100 mg should be prescribed twice weekly for one month, then 200 mg/day until plasma porphyrin levels are normal for at least a month. Initial higher doses may lead to hepatotoxicity as a result of rapid mobilisation of hepatic porphyrin stores.